Polymyositis with documented respiratory involvement, such as interstitial lung disease or pulmonary compromise — use when both the inflammatory myopathy and the pulmonary manifestation are confirmed and charted.
Verified May 8, 2026 · 5 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 9
- Region
- Other
Documentation tips
What should appear in the chart to support M33.21.
Source · Editorial brief grounded in 5 cited references ↓
- Record respiratory symptoms explicitly — dyspnea on exertion, cough, bibasilar crackles — and link them to the polymyositis diagnosis rather than treating them as incidental findings.
- Include pulmonary function test results (DLCO, FVC) and imaging findings (HRCT: ground-glass opacities, honeycombing, or reticulation) that confirm pulmonary involvement.
- Document the basis for the polymyositis diagnosis: proximal muscle weakness by manual muscle testing (MMT), elevated creatine kinase (CK), EMG pattern, and/or biopsy with endomysial CD8+ T-cell infiltrate.
- Distinguish whether this is a new flare, chronic stable ILD, or progression — this supports medical necessity for repeat PFTs, biologics, and immunosuppressive agents.
- Avoid vague language such as 'possible lung involvement' — payer auditors require definitive diagnostic language to support M33.21 over M33.20.
Related CPT procedures
Procedure codes commonly billed with M33.21. Linking the right diagnosis to the right procedure is what establishes medical necessity.
Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis
Common coding pitfalls
The recurring mistakes coders make with M33.21 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Adding J99 (Respiratory disorders in diseases classified elsewhere) alongside M33.21 — the Excludes 1 relationship prohibits this; respiratory involvement is already captured by M33.21.
- Defaulting to M33.20 (organ involvement unspecified) when pulmonary findings are documented — if respiratory involvement is confirmed, M33.21 is required for correct specificity.
- Confusing polymyositis respiratory codes with dermatomyositis equivalents — M33.01 (juvenile dermatomyositis with respiratory involvement) and M33.11 (other dermatomyositis with respiratory involvement) are distinct codes for distinct diagnoses.
- Using M33.21 without documented confirmation of polymyositis — if the underlying diagnosis is dermatomyositis, the correct parent category is M33.0 or M33.1, not M33.2.
- Failing to capture co-existing pulmonary complications separately when they fall outside the scope of the ILD linked to polymyositis — for example, a concurrent pneumonia would still be coded independently.
Clinical context
Source · Editorial summary grounded in 5 cited references ↓
M33.21 applies to patients with polymyositis whose disease has extended to the respiratory system — most commonly interstitial lung disease (ILD) presenting as dyspnea, bibasilar crackles, reduced DLCO on pulmonary function testing, or ground-glass opacities on HRCT. This is a distinct subcategory under M33.2 (Polymyositis) and must not be used when respiratory involvement is absent or unspecified; drop to M33.20 in that case.
A critical Excludes 1 note links M33.21 to J99 (Respiratory disorders in diseases classified elsewhere). J99 is a manifestation code requiring a 'code first' instruction — it should not be coded alongside M33.21 for the same pulmonary manifestation. The respiratory involvement is captured entirely within M33.21; do not layer J99 on top of it.
When polymyositis affects multiple organ systems beyond the respiratory tract, evaluate whether M33.29 (with other organ involvement) is more accurate, or whether additional diagnosis codes are warranted for co-existing complications. Confirm the diagnosis of polymyositis itself is supported by proximal muscle weakness, elevated CK, EMG findings, and/or muscle biopsy before applying any M33.2x code.
Sibling codes
Other billable codes under M33.2 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 5 cited references ↓
01Can I code J99 alongside M33.21 for the pulmonary manifestation?
02What is the difference between M33.21 and M33.20?
03Does M33.21 cover interstitial lung disease associated with polymyositis?
04Which MS-DRGs does M33.21 map to?
05How do I code polymyositis that affects both the lungs and another organ system?
06Is M33.21 appropriate when a patient has polymyositis and incidental mild asthma?
07What documentation supports M33.21 in an audit?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 (effective Oct 1, 2025)
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M30-M36/M33-/M33.21
- 03aapc.comhttps://www.aapc.com/codes/icd-10-codes/M33.21
- 04vsac.nlm.nih.govhttps://vsac.nlm.nih.gov/context/cs/codesystem/ICD10CM/version/2023/code/M33.21/info
- 05outsourcestrategies.comhttps://www.outsourcestrategies.com/blog/code-dermatomyositis-common-rheumatology-disorder/
Mira AI Scribe
Mira's AI scribe captures the specific respiratory findings documented during the encounter — PFT values (DLCO, FVC % predicted), HRCT findings (ground-glass opacities, bibasilar reticulation), and auscultation notes (bibasilar crackles) — and links them explicitly to the polymyositis diagnosis in the assessment. This prevents downcoding to the unspecified M33.20 and blocks an inadvertent J99 stacking error that would trigger an Excludes 1 audit flag.
See how Mira captures M33.21 documentation